5月15日,复宏汉霖股价上涨3.96%,报39.40港元。公司此前授予Sandoz AG其在研产品HLX13的开发、生产和商业化权利,涉及金额至多1.91亿美元。天风证券认为,凭借Sandoz强大的商业化能力,该合作将推动复宏汉霖海外销售峰值提升。此外,公司创新药管线及国际化布局有望在未来几年迎来收获期,包括差异化PD-1单抗等产品。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.